KLK3 and cancer: Analyzing the data from the randomized prostate cancer screening trial in Göteborg, Sweden, which was also a part of ERSPC trial, they reported that for every 1000 previously unscreened men with elevated PSA, the use of the model to determine whether to perform biopsy would reduce biopsy rates by 573, while missing only 31 of 152 low grade cancers and 3 of 40 high grade cancers [103].